Health Care/Hospital

AITRICS to Participate in HIMSS USA 2024

- Three consecutive years of participation in HIMSS USA - Showcasing 'VitalCare' which is an AI Solution for Predicting Patient Deterioration. SEOUL, South Korea, March 12, 2024 /PRNewswire/ -- AITRICS (CEO Kwang joon Kim), a company specializing in medical artificial intelligence (AI) technology...

2024-03-12 22:50 1297

Datasea to Drive Growth in its Acoustic Business via Product Upgrades and U.S. Market Entry

BEIJING, March 12, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative business segments for Acoustics Hi-tech and 5G-AI multimodal communication technology inChina and the U.S., announced today its latest plan for the Company's...

2024-03-12 22:40 2998

Ascend taps Snetor Group for Latin America and medical engineered materials distribution in Europe

HOUSTON, March 12, 2024 /PRNewswire/ -- Ascend Performance Materials announced today that it will expand its relationship with international plastics and chemicals distributor Snetor. Snetor will distribute its polyamide-based engineered materials inLatin America, as well as Ascend's HiDura® MED ...

2024-03-12 22:34 1774

Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting

SHANGHAI, March 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held inSan Diego, USA, from April 5...

2024-03-12 22:00 1365

Zhongchao Inc. Announces Successful Medication Assistance Services for Over 7,000 SLE Patients with Approximately 130,000 Units of Medications

SHANGHAI, March 12, 2024 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin")...

2024-03-12 20:30 2716

GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%

R&D Innovation to Lead the Future, Deepening Customer Value Creation * Sustained High Revenue Growth: GenScript Group's five-year CAGR stands at an impressive 30%, with a strong global operation and stable cash flow. In 2023, the group's best-in-class cell therapy product CARVYKTI®, achieved sa...

2024-03-12 20:15 2183

Metabolon and Cardiff University Centre for Neuropsychiatric Genetics and Genomics Forge Alliance to Propel Multiple Sclerosis Research

Partnership will investigate the underlying disease mechanisms of multiple sclerosis (MS) with the potential of finding new relevant drug targets MORRISVILLE, N.C., March 12, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of li...

2024-03-12 20:05 1716

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

SAN DIEGO and TOKYO and WETTEREN, Belgium, March 12, 2024 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility,...

2024-03-12 20:00 1654

Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD

SAN DIEGO, March 12, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, ...

2024-03-12 20:00 1153

Baird Medical and ExcelFin Acquisition Corp Announce Strategic Update to Business Combination Terms to Reinforce Long-Term Value Creation Opportunity and Alignment with Shareholders

* Baird Medical agreed to subject 30% of its shares to be received in the transaction to an earnout at a$12.50 trading price * Minimum cash condition of $15 million has been waived, cementing certainty and expediency to our transaction close * Upon closing, Baird Medical is expected to trade...

2024-03-12 19:00 2104

Bowtie partners with CUHK Medical Centre to launch the "Medical Insurance + Wellness" Package

* Full reimbursement for 360+ medical packages with transparent prices * One-stop "Medical Insurance + Wellness" solution for "Cashless Hospitalisation" experience * Yearly personalised free check-ups with targeted examinations recommended by doctors HONG KONG, March 12, 2024 /PRNewswire/ --...

2024-03-12 12:01 1361

Innovating the Future: ISoOR 2024 Annual Meeting Achieves Remarkable Success

SINGAPORE, March 12, 2024 /PRNewswire/ -- From March 7 to 8, 2024, the International Society of Organoid Research (ISoOR) convened its 2024 annual meeting, after the successful conference inSingapore last year. This year, the conference was held in the vibrant city ofShanghai, China, reflecting t...

2024-03-12 11:57 1492

TFS HealthScience Unveils Asia Pacific Expansion, Elevating Patient Access and Innovation

LUND, Sweden, March 12, 2024 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), announces its expansion into the Asia Pacific (APAC) region, with the establishment of an operational base in Melbourne, Australia. This strategic move marks a significant m...

2024-03-12 10:52 1601

Mowilex Provides Interior and Exterior Paint for Pioneering Bali International Hospital

Key news highlights: * Mowilex is honored to supply paint for the Bali International Hospital, a 250-bed green facility scheduled to open in 2024. * The Indonesia Healthcare Corporation (IHC) designed the facility and its medical programs to align with global healthcare standards. * Mowilex...

2024-03-12 10:00 1582

Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

SHANGHAI, March 11, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced that the U.S. FDA has granted an orphan drug exclusivity period of seven years for...

2024-03-12 09:28 2420

Casio to Release Uterocervical Observation Camera in the United States, Australia and New Zealand

FDA Registration Completed in the United States and TGA Approval Obtained in Australia TOKYO, March 11, 2024 /PRNewswire/ -- Casio Computer Co., Ltd. announced today that the DZ-C100 COLPOCAMERA, which is designed for uterocervical observation and photography in gynecological settings, and the C...

2024-03-12 09:00 932

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmu...

2024-03-12 08:00 1534

SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada

Milestone Coincides with SK Biopharmaceuticals' Global Plan Expanding Cenobamate Access to More Than 100 Markets Worldwide SEOUL, South Korea and ROME, March 12, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CN...

2024-03-12 08:00 1372

Appointment of Dr Darren Patti to Group Chief Operating Officer

MELBOURNE, Australia, March 12, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr.Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024. Dr. Patti joined Telix in March 2021 to lead the Company'...

2024-03-12 05:44 1330

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

NEW YORK, March 11, 2024 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the "Company") announced today that an aggregate of$50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by a...

2024-03-12 04:30 1636
1234567 ... 799